Deals in Depth: February 2010
Executive Summary
Overall alliance money was low in comparison to January, with no deals rising over the $150mm potential deal value mark. Standing out were GSK's microRNA collaboration with Regulus that could be worth up to $150mm. M&A activity was led, by far, by Merck KGAA's $7.2bn takeover of life sciences company Millipore. Biopharma financing dollars fell in comparison to January numbers, while device financing totals came in higher.